Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.81 |
| ▸ | CNR1 | P21554 | 15/20 | 0.81 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.55 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385133 | 0.89 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL29929142 | 0.89 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL3298491 | 0.89 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL5550044 | 0.88 | CNR2 (0.82) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL4567352 | 0.87 | CNR2 (0.80) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL14454514 | 0.87 | CNR2 (0.80) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL14454509 | 0.87 | CNR2 (0.79) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL14454500 | 0.87 | CNR2 (0.79) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL14454501 | 0.86 | CNR2 (0.64) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL5549479 | 0.86 | CNR2 (0.78) | CNR2CNR1GPR55GPR18 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7183313-B2 | Keto cannabinoids with therapeutic indications | UNIVERSITY OF CONNECTICUT (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183313-B2 | Keto cannabinoids with therapeutic indications | UNIVERSITY OF CONNECTICUT (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155701-A1 | KETO CANNABINOIDS WITH THERAPEUTIC INDICATIONS | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885GPR55 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.